Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SURPASS-CVOT trial assessed tirzepatides effects on cardiovascular endpoints in patients with T2D and established ASCVD, incorporating a unique design, using dulaglutide as the active comparator [8]
Manufacturer's Disclaimer Not recommended for children, or individuals who are pregnant or lactating
After being approved, daily lixisenatide, which is structurally like exenatide and is administered by subcutaneous injectionwas discovered to lower HbA1c by 0.8 to 0.9% [89]
Disclaimer This content is for informational purposes only and does not constitute medical advice or treatment
If you have specific concerns about how your diet interacts with the GLP-1 youre on, consult your health provider
10.1080/13880209.2016.1275026 10 MhaskeD
&srotate=0)
